FODZYME®‘s enzyme blend breaks down FODMAPs before they can cause symptoms, supporting nutritional diversity, dietary flexibility, symptom relief and enhanced quality of life for patients.*
Free FODZYME® Samples for your Clinic
FODZYME® FODMAP-targeted enzymes provide digestive relief — without dietary restriction
10,000+
Providers trust FODZYME®
90%
of 3g fructan broken down within 30 min*1
78%
Report decreased bloating after 4 weeks*2
Effective Relief from FODMAP-Related Symptoms*:
✔️ Bloating and Gas
✔️ Diarrhea
✔️ Abdominal Discomfort
✔️ Constipation
ADVISORS
With a team of experts in medicine, nutrition, and biotechnology, we have developed proprietary digestive enzymes. FODZYME®’s novel fructan hydrolase is the only enzyme available that can break down fructans, the most common FODMAP trigger in IBS.
Dr. William Chey Chief, Division of Gastroenterology & Hepatology at Michigan Medicine
Dr. Thomas Wallach Chief, Division of Pediatric Gastroenterology at SUNY Downstate
WHY FODZYME®?
Your patients have tried everything to find relief — elimination diets, complex protocols, remedies from online influencers. Controlling common digestive issues shouldn’t be this complex, or restrictive.
With FODZYME®, offer your patients an easy, simple way to manage bloating, gas, abdominal discomfort, diarrhea and constipation. No dietary change required.
FODZYME® helps patients enjoy many healthy, nutritious and delicious foods — without worry
** FODZYME® significantly reduces fructan (a FODMAP) in wheat, barley and rye products, not gluten. Fructan is often the real trigger in individuals with non-celiac gluten sensitivity.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
1. Kenny Castro Ochoa, Samant S, Liu A, et al. In Vitro Efficacy of Targeted Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Enzymatic Digestion in a High-Fidelity Simulated Gastrointestinal Environment. Gastro Hep Advances. 2022;2(3):283-290. doi:https://doi.org/10.1016/j.gastha.2022.10.011 (This study was funded by Kiwi Biosciences.) 2. Kaye AJ. Fodzyme at Its Finest: A Case Series Exploring a New Option for IBS Patients. Presented at: The American College of Gastroenterology; October 2024; Philadelphia, PA. Poster P4059. (This study was funded by Kiwi Biosciences.)
.svg "FODZYME logo"){kind=small}
-1.png?width=300&height=300&name=Pexels%20Photo%20by%20Estudio%20Polaroid%20(1)-1.png "Pexels Photo by Estudio Polaroid (1)-1")
